Table 1.
Values for cytotoxic concentration (IC50, μM) of kinase inhibitors on human pancreatic cancer cell lines, BxPC3, Capan 2, Suit 2 and MIA PaCa-2.
| Cell line | Drug | IC5024h μM (95% CI) | IC5048h μM (95% CI) | IC5072h μM (95% CI) |
|---|---|---|---|---|
| BxPC3 | crizotinib | 15.60 (10.03 - 25.28) | 0.005 (indeterminate)* | 7.01 (4.67 - 10.29) |
| cabozantinib | 18.99 (13.95 - 27.12) | 17.33 (12.08 - 27.05) | 13.76 (9.97 - 19.35) | |
| Capmatinib (INC280) | indeterminate | indeterminate | indeterminate | |
| Capan 2 | crizotinib | 29.25 (26.22 - 32.26) | 19.37 (? - 23.31) | 12.08 (9.60 - 14.80) |
| cabozantinib | indeterminate | 38.20 (?- 66.08) | 40.5 (29.90 - 93.93) | |
| capmatinib (INC280) | indeterminate | indeterminate | indeterminate | |
| Suit 2 | crizotinib | 18.97 (? - 24.03) | 13.44 (8.438 - 19.89) | 11.46 (9.868 - 13.27) |
| cabozantinib | 25.41 (19.81 - 36.70) | 36.66 (26.00 - 63.36) | 20.81 (14.10 - 36.80) | |
| capmatinib (INC280) | indeterminate | indeterminate | indeterminate | |
| MIA PaCa-2 | crizotinib | indeterminate | 10.14 (5.787 - 16.21) | 6.41 (4.177 - 9.254) |
| cabozantinib | indeterminate | indeterminate | 14.30 (10.30 - 20.65) | |
| capmatinib (INC280) | indeterminate | indeterminate | indeterminate |
IC50: concentration of kinase inhibitors required to reduce cell viability by 50% as compared to the control cells. CI: confidence interval. Estimated using non-linear fit variable slope four parameters, bottom=0, with Graphpad Prism. ? = not available due to poor curve fit. *no range reported by software, suggesting poor fit and unreliable IC50 value. “?” represents no reportable value by software, suggesting poor fit and unreliable IC50 estimate.